Press release 19 November 2006

Magnecell wins the Impact through Innovation award at the Lord Stafford awards

Magnecell won the Impact through Innovation award at the Lord Stafford awards ceremony last night. The event took place at Alton Towers and over three hundred local and national business people attended.

Magnecell was particularly pleased to win against stiff competition from other innovative companies. "We are delighted that the judges have recognised the world-class nature of our technology," commented Professor Jon Dobson, a co-founder of Magnecell pictured here holding the commemorative bowl that the company won. "Their recognition that Magnecell is expected to play an important part in the emerging field of tissue engineering will help the company with its current fundraising."

Professor Alicia El-Haj, the company's other co-founder, added "I would like to thank Lord Stafford for setting up these awards. They make a big difference to small companies such as Magnecell both in terms of the award itself, but also through the publicity that winning brings."

From left to right. Helen Gascoigne (Keele Innovations Office), Stefan Ogrodzinski (Magnecell), Prof. Jon Dobson (Magnecell), Prof. Alicia El Haj (Magnecell),  Nick Paul (Chairman AWM), Lord Stafford

About Magnecell

Magnecell is opening new channels to therapy with nanotechnology by developing revolutionary tissue engineering products by that use magnetic nanoparticles to overcome major problems associated with the ex vivo growth of human tissues and cells.

The company's technology is based on a Magnetic Force Bioreactor which allows us to control "real life" stress parameters in a sealed bioreactor culture environment. Coupled with world-class expertise in tissue engineering, this puts the company in a unique position in the rapidly emerging field of regenerative medicine.

Additional applications of the core technology cut across many other healthcare markets. As well as allowing tissues to be grown ex vivo on fine scaffolds, the technology aids in stem cell differentiation, produces improved cell-line models for drug screening and can improve levels of recombinant protein expression. Magnecell will enable these applications by selling and licensing assays and bioreactors.

Magnecell's patented technology was developed from biomedical research at Keele University and the North Staffordshire NHS Trust.

Contact

Nicholas Sleep, CEO
Magnecell
Dept. of Biomedical Engineering and Medical Physics
Centre for Science and Technology in Medicine
Keele University
Thornburrow Drive
Hartshill
Stoke-on-Trent
ST4 7QB
United Kingdom

t: +44 (7970) 790906
f: +44 (1782) 717079

e: nicholas.sleep@magnecell.com